Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2021-11-11 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2021-11-11 English
This is to inform you that the Board of Directors of the Company, in their meeting held on Thursday, 11th November, 2021 (commenced at 11.00 A.M. and concluded at 01.30 P.M.), have, inter-alia, ....
Regulatory Filings
2021-11-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation to stock exchanges about a scheduled analyst/investor conference call following the declaration of unaudited financial results for the quarter and half year ended September 30, 2021. It includes details about the conference call timing, access numbers, and participating senior management. The document does not contain the financial results themselves, nor detailed financial statements or analysis. It is a notification about the conference call event related to the Q2 FY 2022 results, not the earnings release or the transcript of the call. Therefore, the document is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement informing the market about the upcoming conference call and results posting, without substantive financial data or the call transcript itself.
2021-11-10 English
Intimation of Post Results (Q2-FY 2021-22) Conference Call
Call Transcript Classification · 95% confidence The document is an intimation to stock exchanges about a scheduled analyst/investor conference call following the declaration of unaudited financial results for the quarter and half year ended September 30, 2021. It includes details about the conference call date, time, access numbers, and participating senior management. The document does not contain the financial results themselves, nor detailed financial statements or analysis. It is a notification about the conference call event related to the Q2 FY 2022 results, not the transcript or the results release itself. Therefore, this document is best classified as a Call Transcript (CT) announcement or invitation. However, since it is only an announcement of the conference call and not the transcript itself, and it is not the earnings release, the closest fitting category is Call Transcript (CT) because it relates directly to the conference call event. Confidence is high as the document clearly states it is an intimation of the conference call post results.
2021-11-10 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges about an upcoming Board Meeting scheduled to consider and approve the company's quarterly and half-yearly un-audited financial results. It is a formal intimation under SEBI regulations about the meeting date and agenda, not the financial results themselves. The document length is only 1636 characters, indicating it is a brief announcement rather than a full report. There is no actual financial data or detailed report content included. Therefore, this document is best classified as a Regulatory Filing (RNS) since it is a regulatory announcement about a board meeting and financial results approval, not the results or report itself.
2021-11-03 English
MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2021 ,inter alia, to consider and approve standalone and consolidated ....
Board/Management Information Classification · 95% confidence The document is a short notice addressed to stock exchanges about an upcoming Board Meeting scheduled to consider and approve the company's quarterly and half-yearly un-audited financial results. It is a formal intimation under SEBI regulations about the meeting date and agenda, not the financial results themselves or any detailed report. The document length is only 1636 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of board meetings and related management information.
2021-11-03 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.